Review
Version 1
This version is not peer-reviewed
The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
Version 1
: Received: 8 April 2021 / Approved: 12 April 2021 / Online: 12 April 2021 (13:55:10 CEST)
A peer-reviewed article of this Preprint also exists.
Martí, C.; Sánchez-Méndez, J.I. The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment. Cancers 2021, 13, 2538. Martí, C.; Sánchez-Méndez, J.I. The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment. Cancers 2021, 13, 2538.
Abstract
Endocrine therapy (ET) has established itself as an efficacious treatment for estrogen receptor-positive (ER+) breast cancers, with a reduction in recurrence rates and increased survival rates. The pre-surgical approach with chemotherapy (NCT) has become a common form of management for large, locally advanced or high-risk tumors. However, a good response to NCT is not usually expected in ER+ tumors. Good results with primary ET, mainly in elderly women, have encouraged studies in other stages of life, and nowadays neoadjuvant endocrine treatment (NET) has become a useful approach to many ER+ breast cancers. The aim of this review is to provide an update on the current state of art regarding the present and the future role of NET.
Keywords
breast cancer; endocrine therapy; neoadjuvant; resistance
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment